139 related articles for article (PubMed ID: 34284438)
1. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA
Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
3. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
[TBL] [Abstract][Full Text] [Related]
4. Role of baseline
Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF
Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Semiautomatic assessment of whole-body tumor burden with 18F-PSMA-1007 in biochemical recurrent prostate cancer.
Cardoza-Ochoa DR; Cristancho-Rojas C; Pérez DJ; Moreno-Izaguirre P; Guzman M; Gutiérrez-Rivera MC; Gaxiola-Mascareño AP; Avila-Rodríguez MA; Rivera-Bravo B
Nucl Med Commun; 2022 Mar; 43(3):332-339. PubMed ID: 34954764
[TBL] [Abstract][Full Text] [Related]
7. Correlations between whole body volumetric parameters of
Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
[TBL] [Abstract][Full Text] [Related]
8. [
Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
[TBL] [Abstract][Full Text] [Related]
9. Predictive significance of intraprostatic volumetric parameters derived from early and standard time 68Ga-PSMA PET/CT images in newly diagnosed prostate cancer patients.
Erdogan EB; Tekce E; Koca S; Aslan N; Toluk O; Aydin M
Nucl Med Commun; 2024 Jul; 45(7):629-641. PubMed ID: 38835183
[TBL] [Abstract][Full Text] [Related]
10.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
11. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
Aksu A; Karahan Şen NP; Tuna EB; Aslan G; Çapa Kaya G
Nucl Med Commun; 2021 May; 42(5):503-509. PubMed ID: 33560717
[TBL] [Abstract][Full Text] [Related]
13. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
Karyağar S; Güven O; Karyağar SS; Arici S; Selvi O; Geredeli Ç; Özülker F
Nucl Med Commun; 2021 Sep; 42(9):1011-1016. PubMed ID: 33958536
[TBL] [Abstract][Full Text] [Related]
14. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
15. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
16. Initial Experience with Volumetric
Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
[TBL] [Abstract][Full Text] [Related]
17. Role of
Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H
Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
[TBL] [Abstract][Full Text] [Related]
18. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
19. The Added Value of
Chen R; Wang Y; Zhu Y; Shi Y; Xu L; Huang G; Liu J
J Nucl Med; 2022 Jan; 63(1):69-75. PubMed ID: 34980667
[No Abstract] [Full Text] [Related]
20. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]